On July 28, IQVIA rose 5.53% in pre-market trading, trading at $227.0 per share, with turnover of $382,700. The stock surged ahead of the regular session as the company released its Q2 fiscal report while benefiting from a wave of analyst upgrades throughout July.

Multiple investment banks have raised their price targets on IQVIA in recent weeks: Baird to $252, HSBC to $240, Leerink Partners to $240, Mizuho to $230, and Evercore ISI to $225, all maintaining outperform or buy ratings. The bullish sentiment builds on the company's strong Q1 results, where adjusted EPS of $2.90 beat the $2.82 consensus by 2.84%, and revenue of $4.151 billion also exceeded estimates. RBC Capital Markets highlighted accelerating organic growth and AI tailwinds as positive signals. The company maintained full-year revenue guidance of $17.15 billion to $17.35 billion, with management emphasizing that the upcoming patent cliff and AI-driven innovation demand will continue to boost CRO service requirements.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)